Innovate UK has awarded Amprologix £1M of Biomedical Catalyst funding to continue the Tobraderm project
1st March 2024
Amprologix is delighted to receive confirmation of its success in securing a £1M Biomedical Catalyst award from Innovate UK for its Tobraderm project. The project will advance the company’s NI01 lead compound through late-preclinical testing for common skin and wound infections.
For more information about Innovate UK and the Biomedical Catalyst award funding visit:
